Tag Archives: HER2-positive

Pertuzumab Plus Herceptin Shows Promise in Early Breast Cancer

Just after four cycles of neoadjuvant use, the combination of Roche’s pertuzumab,  Herceptin (trastuzumab) and chemotherapy improved the rate of complete tumor disappearance by more than half compared to conventional therapy in patients with HER2-positive breast cancer.  The results came … Continue reading

Posted in Breast cancer, Cancer | Tagged , , , , , , , | Comments Off on Pertuzumab Plus Herceptin Shows Promise in Early Breast Cancer